Abstract 104: A machine learning approach to predict and mitigate artifact variants for molecular residual disease detection.

Abstract Tumor-informed molecular residual disease (MRD) detection requires removal of artifacts from tissue whole-genome sequencing (WGS), which can cause false positive calls in plasma, even in healthy donors (HDs). To address this, we developed a machine-learning framework to score the reliability of tissue variants, thereby improving the specificity and sensitivity of tissue-informed MRD detection. We used retrospective WGS data from 47 tumor and matched normal (T&MN) samples across a diverse set of cancer types. Somatic single nucleotide variants (SNV) were identified via a consensus calling strategy from multiple variant callers. We extracted variant features from each caller relating to signal amount and quality, and subsequently engineered additional features to qualify strand bias, variant- and locus-specific characteristics. To generate training labels, SNV were evaluated in matched patient plasma and 107 HD plasmas. Variants with high mean VAF across the HD plasma samples were labeled as likely artifacts (∼16k), while those with high VAF in the matched patient plasma were labeled as true tumor variants (∼187k). An extremely randomized trees model was then trained using 17 informative, uncorrelated features. Model performance was measured by calculating the area under the curve (AUC) from a receiver operating characteristic (ROC) analysis. Our model distinguished true tumor variants from likely artifacts with a cross-validated ROC AUC of 0.94 and an average precision of 0.99. Key predictive features from the tissue included tumor VAF, mutant allele count, and a read orientation quality metric. In each patient, the model-derived confidence score demonstrated a strong and negative correlation with the mean VAF in the HD plasma samples (median Spearman ρ = -0.30), outperforming a previous method (median ρ = -0.17). This work provides a data-driven framework that systematically ranks and filters tissue variants by their likelihood of being artifacts. By enhancing the reliability of mutation calls from the tissue sample, this method can improve the accuracy of tissue-informed MRD detection. Citation Format: Violeta B. Guthrie, Aamir Shahpurwalla, Daryanaz Dargahi, Onur Sakarya, Spenser Alexander, Tina Wang, Fei Lu, Alexander Hsieh, Ryan Ptashkin, Matthew Rabinowitz, Eser Kirkizlar, Ahmet Zehir. A machine learning approach to predict and mitigate artifact variants for molecular residual disease detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 104.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-104
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 104: A machine learning approach to predict and mitigate artifact variants for molecular residual disease detection.

Onur Sakarya, Ahmet Zehir, Ryan Ptashkin, Aamir Shahpurwalla et al.
Cancer Research
Cancer Genomics and Diagnostics
article

Abstract 104: A machine learning approach to predict and mitigate artifact variants for molecular residual disease detection.

Onur Sakarya, Ahmet Zehir, Ryan Ptashkin, Aamir Shahpurwalla, Matt Rabinowitz, Alexander Hsieh, Seema Alexander, Daryanaz Dargahi, Fei Lu, Tina Wang, Eser Kirkizlar, Violeta B. Guthrie
article en

Abstract

Abstract Tumor-informed molecular residual disease (MRD) detection requires removal of artifacts from tissue whole-genome sequencing (WGS), which can cause false positive calls in plasma, even in healthy donors (HDs). To address this, we developed a machine-learning framework to score the reliability of tissue variants, thereby improving the specificity and sensitivity of tissue-informed MRD detection. We used retrospective WGS data from 47 tumor and matched normal (T&MN) samples across a diverse set of cancer types. Somatic single nucleotide variants (SNV) were identified via a consensus calling strategy from multiple variant callers. We extracted variant features from each caller relating to signal amount and quality, and subsequently engineered additional features to qualify strand bias, variant- and locus-specific characteristics. To generate training labels, SNV were evaluated in matched patient plasma and 107 HD plasmas. Variants with high mean VAF across the HD plasma samples were labeled as likely artifacts (∼16k), while those with high VAF in the matched patient plasma were labeled as true tumor variants (∼187k). An extremely randomized trees model was then trained using 17 informative, uncorrelated features. Model performance was measured by calculating the area under the curve (AUC) from a receiver operating characteristic (ROC) analysis. Our model distinguished true tumor variants from likely artifacts with a cross-validated ROC AUC of 0.94 and an average precision of 0.99. Key predictive features from the tissue included tumor VAF, mutant allele count, and a read orientation quality metric. In each patient, the model-derived confidence score demonstrated a strong and negative correlation with the mean VAF in the HD plasma samples (median Spearman ρ = -0.30), outperforming a previous method (median ρ = -0.17). This work provides a data-driven framework that systematically ranks and filters tissue variants by their likelihood of being artifacts. By enhancing the reliability of mutation calls from the tissue sample, this method can improve the accuracy of tissue-informed MRD detection. Citation Format: Violeta B. Guthrie, Aamir Shahpurwalla, Daryanaz Dargahi, Onur Sakarya, Spenser Alexander, Tina Wang, Fei Lu, Alexander Hsieh, Ryan Ptashkin, Matthew Rabinowitz, Eser Kirkizlar, Ahmet Zehir. A machine learning approach to predict and mitigate artifact variants for molecular residual disease detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 104.

Cancer ResearchVol. 86(7_Supplement)
Natera (United States) (US)
Openalex Percentile: Top 10%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.